Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

Septerna SVP Daniel D. Long exercised and sold 15,000 shares for ~$533,000 on June 22, 2026, reducing his direct holdings by 13.46%. The analyst suggests this appears to be routine income supplementation rather than a loss of confidence, as Long retains 96,412 shares and 36,000 unexercised options. Septerna, a clinical-stage biotech developing GPCR-targeted therapies, has shown positive phase 1 results for SEP-631 and maintains partnerships with Novo Nordisk.